Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TET3 | O43151 | 2/20 | 0.41 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.41 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.41 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817038 | 0.92 | AKR1C1 (0.68) | AKR1C1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL13456896 | 0.92 | AKR1C1 (0.62) | AKR1C1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL27691762 | 0.90 | AKR1C1 (0.66) | AKR1C1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL3210967 | 0.87 | AKR1C1 (0.47) | AKR1C1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL22090138 | 0.87 | HDAC1 (0.53) | AKR1C1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL5106245 | 0.83 | LMNA (0.45) | AKR1C1ALDH1A1L3MBTL1 | |
| SCHEMBL12742660 | 0.81 | OPRD1 (0.44) | AKR1C1TSHRALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL350266 | 0.80 | APP (0.58) | AKR1C1KMT2AMEN1TSHRAPP | |
| SCHEMBL31016196 | 0.79 | AKR1C1 (0.83) | AKR1C1KMT2AMEN1ALDH1A1CYP2C19 | |
| SCHEMBL6391 | 0.79 | AKR1C1 (0.83) | AKR1C1KMT2AMEN1ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-108912111-B | Compounds and pharmaceutical compositions | 赛克里翁治疗有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-7776874-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2009123986-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | WO | disclosed |
| EP-1756063-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | INCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| CN-101001842-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | AKR1C1 1849/4885KMT2A 4250/4885MEN1 2447/4885 |
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | AKR1C1 1849/4885KMT2A 4250/4885MEN1 2447/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AKR1C1 38/4885KMT2A 3418/4885MEN1 379/4885 |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | HSD11B1, NR3C2, SRD5A1 | AKR1C1 18/4885KMT2A 2235/4885MEN1 2998/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AKR1C1 38/4885KMT2A 3418/4885MEN1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.